AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

Inclusion Criteria

• •1. Diagnosis of favorable-risk acute myeloid leukemia (AML) according to revised 2017 European LeukemiaNet genetic risk stratification and are not immediate candidates for allogeneic stem cell transplant.
• •2. Aged 18-64 years.
• •3. Patients who have received remission induction therapy and 3-4 HiDAC or medium-dose cytarabine-based consolidation and are in their first remission.
• •4. ECOG performance status of \< or = 3.
• •5. Adequate organ function as follows:
• •1. Serum total bilirubin \< or = to 3 X the Upper Limit of Normal (ULN)
• •2. Aspartate Transaminase and alanine transaminase \< or = to 3 x ULN
• •3. Ccr（Creatinine Clearance Rate) \> or ＝60 ml/min
• •4. Left ventricular ejection fraction \> or ＝50% determined by ultrasound.
• •6. For females of childbearing age, they should have a negative serum or urine pregnancy test within 10 to 14 days of enrolling.
• •7. For males of childbearing age, they should take effective contraceptive methods throughout the treatment period and up to 30 days after discontinuing treatment.
• •8. Ability to understand and sign informed consent.